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The recent commotion about the risk of unexpected malignan-
cy during myoma morcellation may have divergent conse-
quences. Some are positive for future women’s health care,
while others may be negative. On the positive side, the ‘sar-
coma awareness’ will lead to improvements in the diagnosis
of myometrial lesions including leiomyosarcoma and in the
technical aspects of safer, ‘spill-free’ myoma removal. On the
negative side, the fear of an unexpected sarcoma may lead to
unnecessary, more invasive surgery and avoidance of minimal
invasive surgery—out of an abundance of caution.
The turmoil about the unexpected sarcoma, echoed and
amplified in the press worldwide, may lead patients and doc-
tors to have all too much faith in the adage that ‘any fibroid is a
sarcoma, until proven otherwise’. Although this precautionary
principle should be integrated in the decision making of any
gynecologist before proceeding with a myomectomy, it could
also have perverse effects. The latter may especially be true
when confronted with the incidental finding of a well-defined
myometrial lesion [1] on ultrasound examination. Somemight
even contemplate the introduction of a ‘screening program’
for sarcoma—‘because they care for their patients’. Indeed,
the (public) perception of a fibroid being a ‘potential sarcoma’
could lead to following fallacious reasoning as illustrated in
Fig. 1. There is no doubt that a leiomyosarcoma is a very
aggressive and often lethal disease. If the lesion is confined
to the uterus, the 5-year survival is 50 % [2], but only 20 % in
case of more extended disease [3]. The cumulative risk for
developing a sarcoma is about 5/10,000 [4]. This means that
in a cohort of 20,000 women, 10 will develop a sarcoma.
Depending on the stage of the cancer at diagnosis, 5 to 8 of
those 10 women will ultimately die of the disease. Figure 1
summarizes what would happen if, motivated by the high
mortality rates and by the repetitive alarming press releases,
a screening program for sarcoma was launched at age 50.
Given the 50 % incidence of fibroids at age 50, and based
on the adage that ‘any fibroid is a sarcoma, until proven oth-
erwise’, half of the screened population would be ‘screen pos-
itive’. Because of the diagnostic unreliability to distinguish
between a benign myoma and a malignant leiomyosarcoma
(LMS), the safest way to perform a ‘spill-free tumor removal’
would be a total abdominal hysterectomy. One may hypothe-
size that at age 50, half of the sarcomas would be picked up
and that this would be at an early stage, confined to the uterus.
Half of these women would therefore be curable, while 2 to 3
women would still die from the sarcoma. However, an abdom-
inal hysterectomy is not free of risk. A mortality rate for ab-
dominal hysterectomy of 1.5/1000 has been reported [5]. This
would mean that out of the 10,000 women undergoing a hys-
terectomy, 15 women would die due to the surgery. Finally, in
the “screen negative” group of women at age 50, one may
assume that 5 women would develop a sarcoma later in life.
These would then be diagnosed in a later stage of the disease
and 3 to 4 of these women would die of the disease. Based on
this simulation, the mortality rate in the screened group would
be between 10 and 11/10,000 versus 2.5 and 4/10,000 in the
unscreened group. The ‘collateral damage’ of screening a
group of 20,000 women would be 12 to 17 extra deaths.
I acknowledge that this simulation based on a few selected
publications is simplistic and that the figures are prone to bias.
However, I mean it to illustrate the real danger of generalizing
partial knowledge in medicine.
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The risk of fibroid morcellation is an important women’s
health issue and cannot be underestimated. However, it should
be put in the right perspective as done by Brölmann et al. [6].
Both blunt denial of the problem and overreaction may have
deleterious consequences.
The incidental diagnosis of a fibroid in an asymptomatic
woman is rarely an indication for surgery.
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